請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16797
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 吳漢忠(Han-Chung Wu) | |
dc.contributor.author | Tsung-Wei Hou | en |
dc.contributor.author | 侯宗緯 | zh_TW |
dc.date.accessioned | 2021-06-07T23:46:16Z | - |
dc.date.copyright | 2014-10-09 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-06-18 | |
dc.identifier.citation | Allan, A.L., and Keeney, M. (2010). Circulating tumor cell analysis: technical and statistical considerations for application to the clinic. Journal of oncology 2010, 426218.
Allen, T.M., and Cullis, P.R. (2013). Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 65, 36-48. Baeuerle, P.A., and Gires, O. (2007). EpCAM (CD326) finding its role in cancer. British journal of cancer 96, 417-423. Balic, M., Williams, A., Lin, H., Datar, R., and Cote, R.J. (2013). Circulating tumor cells: from bench to bedside. Annual review of medicine 64, 31-44. Bergerson, J. (2012). Importance of Screening for Cancer Beyond the Colon in HNPCC. Am J Gastroenterol 107, S359-S359. Camerini, A., Valsuani, C., Mazzoni, F., Siclari, O., Puccetti, C., Donati, S., Rondini, M., Tartarelli, G., Puccinelli, P., Di Costanzo, F., et al. (2010). Phase II trial of single-agent oral vinorelbine in elderly (> or =70 years) patients with advanced non-small-cell lung cancer and poor performance status. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 21, 1290-1295. Carpenter, G., and Brewer, M.R. (2009). EpCAM: Another Surface-to-Nucleus Missile. Cancer cell 15, 165-166. Chames, P., Van Regenmortel, M., Weiss, E., and Baty, D. (2009). Therapeutic antibodies: successes, limitations and hopes for the future. British journal of pharmacology 157, 220-233. Chan, A.T., and Giovannucci, E.L. (2010). Primary prevention of colorectal cancer. Gastroenterology 138, 2029-2043 e2010. Chang, D.K., Chiu, C.Y., Kuo, S.Y., Lin, W.C., Lo, A., Wang, Y.P., Li, P.C., and Wu, H.C. (2009a). Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors. The Journal of biological chemistry 284, 12905-12916. Chang, D.K., Lin, C.T., Wu, C.H., and Wu, H.C. (2009b). A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer. PloS one 4, e4171. Chang, H.I., and Yeh, M.K. (2012). Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. International journal of nanomedicine 7, 49-60. Chidambaram, M., Manavalan, R., and Kathiresan, K. (2011). Nanotherapeutics to overcome conventional cancer chemotherapy limitations. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 14, 67-77. Cianfrocca, M., Lee, S., Von Roenn, J., Tulpule, A., Dezube, B.J., Aboulafia, D.M., Ambinder, R.F., Lee, J.Y., Krown, S.E., and Sparano, J.A. (2010). Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer 116, 3969-3977. Das, M., Mohanty, C., and Sahoo, S.K. (2009). Ligand-based targeted therapy for cancer tissue. Expert opinion on drug delivery 6, 285-304. Davis, M.E., Chen, Z.G., and Shin, D.M. (2008). Nanoparticle therapeutics: an emerging treatment modality for cancer. Nature reviews Drug discovery 7, 771-782. Denzel, S., Maetzel, D., Mack, B., Eggert, C., Barr, G., and Gires, O. (2009). Initial activation of EpCAM cleavage via cell-to-cell contact. BMC cancer 9, 402. Dietvorst, M.H., and Eskens, F.A. (2013). Current and Novel Treatment Options for Metastatic Colorectal Cancer: Emphasis on Aflibercept. Biologics in therapy 3, 25-33. Drummond, D.C., Meyer, O., Hong, K., Kirpotin, D.B., and Papahadjopoulos, D. (1999). Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacological reviews 51, 691-743. Edge, S.B., and Compton, C.C. (2010). The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Annals of surgical oncology 17, 1471-1474. Eskander, R.N., and Tewari, K.S. (2013). Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer. Clinical pharmacology : advances and applications 5, 55-61. Eyer, L., and Hruska, K. (2012). Single-domain antibody fragments derived from heavy-chain antibodies: a review. Vet Med-Czech 57, 439-513. Fakih, M.G. (2011). Making sense of anti-EGFR plus oxaliplatin-based therapy in the first-line treatment of metastatic colorectal cancer. Future oncology 7, 223-226. Finek, J., Holubec, L., Jr., Svoboda, T., Sefrhansova, L., Pavlikova, I., Votavova, M., Sediva, M., Filip, S., Kozevnikova, R., and Kormunda, S. (2009). A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer. Anticancer research 29, 667-670. Flajnik, M.F., Deschacht, N., and Muyldermans, S. (2011). A case of convergence: why did a simple alternative to canonical antibodies arise in sharks and camels? PLoS biology 9, e1001120. Giannopoulou, E., Antonacopoulou, A., Matsouka, P., and Kalofonos, H.P. (2009). Autophagy: novel action of panitumumab in colon cancer. Anticancer research 29, 5077-5082. Gires, O., Klein, C.A., and Baeuerle, P.A. (2009). On the abundance of EpCAM on cancer stem cells. Nature reviews Cancer 9, 143; author reply 143. Giuliani, F., and Colucci, G. (2007). Cetuximab in colon cancer. The International journal of biological markers 22, S62-70. Goel, S., Bauer, R.J., Desai, K., Bulgaru, A., Iqbal, T., Strachan, B.K., Kim, G., Kaubisch, A., Vanhove, G.F., Goldberg, G., et al. (2007). Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineered(TM) monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors. Annals of Oncology 18, 1704-1707. Griffiths, A.D., Malmqvist, M., Marks, J.D., Bye, J.M., Embleton, M.J., McCafferty, J., Baier, M., Holliger, K.P., Gorick, B.D., Hughes-Jones, N.C., et al. (1993). Human anti-self antibodies with high specificity from phage display libraries. The EMBO journal 12, 725-734. Hazewinkel, Y., and Dekker, E. (2011). Colonoscopy: basic principles and novel techniques. Nature reviews Gastroenterology & hepatology 8, 554-564. Higa, R. (2011). [Colorectal cancer: epidemiology and primary profilaxis]. Acta gastroenterologica Latinoamericana 41, 70-73. Holohan, C., Van Schaeybroeck, S., Longley, D.B., and Johnston, P.G. (2013). Cancer drug resistance: an evolving paradigm. Nature reviews Cancer 13, 714-726. Immordino, M.L., Dosio, F., and Cattel, L. (2006). Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. International journal of nanomedicine 1, 297-315. Jacobsson, K., and Frykberg, L. (2001). Shotgun phage display cloning. Combinatorial chemistry & high throughput screening 4, 135-143. Jager, M., Schoberth, A., Ruf, P., Hess, J., Hennig, M., Schmalfeldt, B., Wimberger, P., Strohlein, M., Theissen, B., Heiss, M.M., et al. (2012). Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3). Cancer research 72, 24-32. Jasperson, K.W., Tuohy, T.M., Neklason, D.W., and Burt, R.W. (2010). Hereditary and Familial Colon Cancer. Gastroenterology 138, 2044-2058. Lee, T.Y., Lin, C.T., Kuo, S.Y., Chang, D.K., and Wu, H.C. (2007). Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery. Cancer research 67, 10958-10965. Lee, T.Y., Wu, H.C., Tseng, Y.L., and Lin, C.T. (2004). A novel peptide specifically binding to nasopharyngeal carcinoma for targeted drug delivery. Cancer research 64, 8002-8008. Lin, C.W., Liao, M.Y., Lin, W.W., Wang, Y.P., Lu, T.Y., and Wu, H.C. (2012). Epithelial cell adhesion molecule regulates tumor initiation and tumorigenesis via activating reprogramming factors and epithelial-mesenchymal transition gene expression in colon cancer. The Journal of biological chemistry 287, 39449-39459. Litvinov, S.V., Velders, M.P., Bakker, H.A.M., Fleuren, G.J., and Warnaar, S.O. (1994). Ep-Cam - a Human Epithelial Antigen Is a Homophilic Cell-Cell Adhesion Molecule. Journal of Cell Biology 125, 437-446. Liu, I.J., Hsueh, P.R., Lin, C.T., Chiu, C.Y., Kao, C.L., Liao, M.Y., and Wu, H.C. (2004). Disease-specific B Cell epitopes for serum antibodies from patients with severe acute respiratory syndrome (SARS) and serologic detection of SARS antibodies by epitope-based peptide antigens. The Journal of infectious diseases 190, 797-809. Lo, A., Lin, C.T., and Wu, H.C. (2008). Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. Molecular cancer therapeutics 7, 579-589. Lopes, G., Quesada, J., Ahn, E., Flores, A., Ribeiro, A., and Rocha-Lima, C.M. (2007). Oxaliplatin and fixed-rate infusional gemcitabine in the second-line treatment of patients with metastatic colon cancer: final results of a Phase II trial prematurely closed as a result of poor accrual. Clinical colorectal cancer 6, 641-645. Lu, R.M., Chang, Y.L., Chen, M.S., and Wu, H.C. (2011). Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. Biomaterials 32, 3265-3274. Maetzel, D., Denzel, S., Mack, B., Canis, M., Went, P., Benk, M., Kieu, C., Papior, P., Baeuerle, P.A., Munz, M., et al. (2009). Nuclear signalling by tumour-associated antigen EpCAM. Nature cell biology 11, 162-171. Maher, J., and Adami, A.A. (2013). Antitumor Immunity: Easy as 1, 2, 3 with Monoclonal Bispecific Trifunctional Antibodies? Cancer research 73, 5613-5617. Malam, Y., Loizidou, M., and Seifalian, A.M. (2009). Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends in pharmacological sciences 30, 592-599. Mansour, M., and Mourad, C. (2013). Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer. Cancer chemotherapy and pharmacology 72, 429-435. Markman, M., Moon, J., Wilczynski, S., Lopez, A.M., Rowland, K.M., Jr., Michelin, D.P., Lanzotti, V.J., Anderson, G.L., and Alberts, D.S. (2010). Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecologic oncology 116, 323-325. Marschner, N., Ruttinger, D., Zugmaier, G., Nemere, G., Lehmann, J., Obrist, P., Baeuerle, P.A., Wolf, A., Schmidt, M., Abrahamsson, P.A., et al. (2010). Phase II Study of the Human Anti-Epithelial Cell Adhesion Molecule Antibody Adecatumumab in Prostate Cancer Patients with Increasing Serum Levels of Prostate-Specific Antigen after Radical Prostatectomy. Urol Int 85, 386-395. Marshall, J. (2005). The role of bevacizumab as first-line therapy for colon cancer. Seminars in oncology 32, S43-47. Mashaghi, S., Jadidi, T., Koenderink, G., and Mashaghi, A. (2013). Lipid nanotechnology. International journal of molecular sciences 14, 4242-4282. Matsukawa, S., Shiratori, T., Kugimiya, M., Matsuo, S., Kaji, S., and Aoyama, Y. (2010). [A recurrence after surgery for colon cancer with metastases of the liver and periaortic lymph nodes, with CR achieved by using bevacizumab+mFOLFOX6]. Gan to kagaku ryoho Cancer & chemotherapy 37, 1389-1391. Mbah, N. (2009). Hospital frequency of large bowel cancer: factors thought to influence outcome. Nigerian journal of clinical practice 12, 37-41. Misra, R., Acharya, S., and Sahoo, S.K. (2010). Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug discovery today 15, 842-850. Moiel, D., and Thompson, J. (2011). Early detection of colon cancer-the kaiser permanente northwest 30-year history: how do we measure success? Is it the test, the number of tests, the stage, or the percentage of screen-detected patients? The Permanente journal 15, 30-38. Munz, M., Kieu, C., Mack, B., Schmitt, B., Zeidler, R., and Gires, O. (2004). The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 23, 5748-5758. Mutch, D.G., Orlando, M., Goss, T., Teneriello, M.G., Gordon, A.N., McMeekin, S.D., Wang, Y., Scribner, D.R., Jr., Marciniack, M., Naumann, R.W., et al. (2007). Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 25, 2811-2818. Nagrath, S., Sequist, L.V., Maheswaran, S., Bell, D.W., Irimia, D., Ulkus, L., Smith, M.R., Kwak, E.L., Digumarthy, S., Muzikansky, A., et al. (2007). Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450, 1235-1239. Niedzwiecki, D., Bertagnolli, M.M., Warren, R.S., Compton, C.C., Kemeny, N.E., Benson, A.B., Eckhardt, S.G., Alberts, S., Porjosh, G.N., Kerr, D.J., et al. (2011). Documenting the Natural History of Patients With Resected Stage II Adenocarcinoma of the Colon After Random Assignment to Adjuvant Treatment With Edrecolomab or Observation: Results From CALGB 9581. Journal of Clinical Oncology 29, 3146-3152. Oliveira, S., Heukers, R., Sornkom, J., Kok, R.J., and van Bergen En Henegouwen, P.M. (2013). Targeting tumors with nanobodies for cancer imaging and therapy. J Control Release 172, 607-617. Ozkumur, E., Shah, A.M., Ciciliano, J.C., Emmink, B.L., Miyamoto, D.T., Brachtel, E., Yu, M., Chen, P.I., Morgan, B., Trautwein, J., et al. (2013). Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Science translational medicine 5, 179ra147. Peppone, L.J., Mahoney, M.C., Cummings, K.M., Michalek, A.M., Reid, M.E., Moysich, K.B., and Hyland, A. (2008). Colorectal cancer occurs earlier in those exposed to tobacco smoke: implications for screening. J Cancer Res Clin 134, 743-751. Perrigue, M.M., Kantor, E.D., Hastert, T.A., Patterson, R., Potter, J.D., Neuhouser, M.L., and White, E. (2013). Eating frequency and risk of colorectal cancer. Cancer Cause Control 24, 2107-2115. Pujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P.A., Volgger, B., Vergote, I., Pignata, S., Ferrero, A., et al. (2010). Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 28, 3323-3329. Revets, H., De Baetselier, P., and Muyldermans, S. (2005). Nanobodies as novel agents for cancer therapy. Expert Opin Biol Th 5, 111-124. Riethdorf, S., Fritsche, H., Muller, V., Rau, T., Schindlbeck, C., Rack, B., Janni, W., Coith, C., Beck, K., Janicke, F., et al. (2007). Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clinical cancer research : an official journal of the American Association for Cancer Research 13, 920-928. Saul, J.M., Annapragada, A.V., and Bellamkonda, R.V. (2006). A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J Control Release 114, 277-287. Schmitz, U., Versmold, A., Kaufmann, P., and Frank, H.G. (2000). Phage display: a molecular tool for the generation of antibodies--a review. Placenta 21 Suppl A, S106-112. Seimetz, D., Lindhofer, H., and Bokemeyer, C. (2010). Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer treatment reviews 36, 458-467. Siegel, R., Desantis, C., and Jemal, A. (2014). Colorectal cancer statistics, 2014. CA: a cancer journal for clinicians 64, 104-117. Siegel, R., Naishadham, D., and Jemal, A. (2012). Cancer statistics, 2012. CA: a cancer journal for clinicians 62, 10-29. Sieuwerts, A.M., Kraan, J., Bolt, J., van der Spoel, P., Elstrodt, F., Schutte, M., Martens, J.W., Gratama, J.W., Sleijfer, S., and Foekens, J.A. (2009). Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. Journal of the National Cancer Institute 101, 61-66. Slingerland, M., Guchelaar, H.J., and Gelderblom, H. (2012). Liposomal drug formulations in cancer therapy: 15 years along the road. Drug discovery today 17, 160-166. Smith, G.P. (1985). Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228, 1315-1317. Sparano, J.A., Makhson, A.N., Semiglazov, V.F., Tjulandin, S.A., Balashova, O.I., Bondarenko, I.N., Bogdanova, N.V., Manikhas, G.M., Oliynychenko, G.P., Chatikhine, V.A., et al. (2009). Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27, 4522-4529. Sweetser, S., Smyrk, T.C., and Sinicrope, F.A. (2013). Serrated Colon Polyps as Precursors to Colorectal Cancer. Clin Gastroenterol H 11, 760-767. Trojan, J., Lubomierski, N., Lehnert, T., Engels, K., Zeuzem, S., and Bechstein, W.O. (2008). Neoadjuvant treatment with cetuximab, 5-Fluorouracil, folinic Acid and oxaliplatin in unresectable retroperitoneal recurrent colon cancer. Zeitschrift fur Gastroenterologie 46, 776-779. Vaughan, T.J., Williams, A.J., Pritchard, K., Osbourn, J.K., Pope, A.R., Earnshaw, J.C., McCafferty, J., Hodits, R.A., Wilton, J., and Johnson, K.S. (1996). Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nature biotechnology 14, 309-314. Visvader, J.E., and Lindeman, G.J. (2008). Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature reviews Cancer 8, 755-768. Weitz, J., Koch, M., Debus, J., Hohler, T., Galle, P.R., and Buchler, M.W. (2005). Colorectal cancer. Lancet 365, 153-165. Went, P., Vasei, M., Bubendorf, L., Terracciano, L., Tornillo, L., Riede, U., Kononen, J., Simon, R., Sauter, G., and Baeuerle, P.A. (2006). Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. British journal of cancer 94, 128-135. Went, P.T., Lugli, A., Meier, S., Bundi, M., Mirlacher, M., Sauter, G., and Dirnhofer, S. (2004). Frequent EpCam protein expression in human carcinomas. Human pathology 35, 122-128. Wu, H.C., and Chang, D.K. (2010). Peptide-mediated liposomal drug delivery system targeting tumor blood vessels in anticancer therapy. Journal of oncology 2010, 723798 . Zarschler, K., Witecy, S., Kapplusch, F., Foerster, C., and Stephan, H. (2013). High-yield production of functional soluble single-domain antibodies in the cytoplasm of Escherichia coli. Microbial cell factories 12, 97. Zlot, A.I., Silvey, K., Newell, N., Coates, R.J., and Leman, R. (2012). Family History of Colorectal Cancer: Clinicians' Preventive Recommendations and Patient Behavior. Prev Chronic Dis 9. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16797 | - |
dc.description.abstract | 上皮細胞黏附因子 (EpCAM),屬第一型的穿膜醣蛋白,幾乎存在於所有的腺狀細胞癌及鱗狀上皮細胞癌並有高度的表現量。過去文獻顯示,此蛋白也出現在癌幹細胞中,並有助於腫瘤的生長。其中又以大腸直腸癌,擁有極高度的EpCAM表現量與高居首位的表現頻率。在我們先前的研究指出,EpCAM在大腸癌幹細胞中具有調節腫瘤細胞起始的能力,又與癌症的惡性程度有密切的相關性。因此在本研究中,我們利用噬菌體展現胜肽庫 (phage-displayed peptide library) 及嗜菌體呈現之人類單鏈抗體庫 (phage-displayed human naïve scFv library) 篩選出一些可以與上皮細胞黏附因子之細胞外域 (EpEX) 結合的新穎胜肽配體或單鏈抗體,並以酵素結合免疫吸附分析、流式細胞儀、免疫螢光法及活體內腫瘤導向分析,驗證與EpEX結合之專一性和結合強度。其次,將EpEX標的胜肽或單鏈抗體接於螢光微脂體上,發現能提升微脂體對大腸癌細胞結合和內化的效率。此外,利用結合標的胜肽與包覆癌症藥物之微脂體,治療異體移植大腸癌細胞的免疫缺陷老鼠,可得到較佳的腫瘤抑制效果及療效。綜觀上述結果,此標的胜肽具有作為標靶藥物傳輸系統、治療大腸癌之潛力,根據對於腫瘤細胞標的專一性及降低化療藥物對正常組織細胞之毒性,進而延長整體病人臨床存活率是可以被期待的。 | zh_TW |
dc.description.abstract | Epithelial cell adhesion molecule (EpCAM) is a type I transmembrane glycoprotein overexpressed in almost all adeno and squamous cell carcinoma. It has also been shown that EpCAM is expressed on cancer stem cells and contributes to tumor growth. Colon cancer has the highest frequency of high-level EpCAM expression. Our previous study indicates that EpCAM plays an important role in regulating cancer-initiating abilities in colon cancer stem cells and is correlated with tumor malignancy. In this study, we used a phage-displayed peptide library and a human naïve scFv library to isolate two novel peptides and scFvs that bind to EpCAM's extracellular domain (EpEX). The specificity and binding affinity of EpEX-selected peptides and scFvs were confirmed by ELISA, flow cytometry, immunofluorescence and in vivo tumor homing assays. Next, conjugation of EpEX-specific peptides or scFvs to liposomal SRB can potentially improve binding and internalization efficiency of liposomes to colon cancer cells. Furthermore, the therapeutic index and the survival rates of mice bearing human colon cancer xenografts treated with liposomal doxorubicin or vinorelbine were increased significantly by conjugating EpEX-specific peptide to the liposomal drug. These results revealed the potential benefit of EpEX-specific peptide at enhancing the therapeutic efficacy of targeted drug delivery in the treatment of colon cancer. According to afford tumor specificity and limitless toxicity for normal tissues, prolonging the survival of the patient in clinical scenarios is expected. | en |
dc.description.provenance | Made available in DSpace on 2021-06-07T23:46:16Z (GMT). No. of bitstreams: 1 ntu-103-R01450001-1.pdf: 3290545 bytes, checksum: 8dbceed413f13bc6d507f7169c38d485 (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | 中文摘要 1
Abstract 2 Contents 3 List of abbreviations 5 Introduction 8 1.1 Epidemiology of colorectal cancer 8 1.2 Pathogenesis of colorectal cancer 9 1.3 Detection and diagnosis of colorectal cancer 10 1.4 Treatment of colorectal cancer 12 1.5 Epithelial cell adhesion molecule (EpCAM) 14 1.6 EpCAM expression on cancer stem cells (CSCs) 16 1.7 Circulating tumor cells (CTC) detection and characterization 17 1.8 Phage display technique 17 1.9 Anticancer nanotechnology-delivery system 19 Materials and Methods 22 2.1 Cell lines and cell culture 22 2.2 Ph.D.-12 random peptide library and biopanning procedures 22 2.3 Tranfection with lentiviral vectors expressing shRNA 23 2.4 Western blotting 24 2.5 ELISA screening of selected phage clones 25 2.6 DNA sequencing and computer analysis 26 2.7 Flow cytometric analysis 26 2.8 Expression and purification of soluble scFv 27 2.9 Internalization assay of scFv 28 2.10 In vivo homing experiments and tissue distribution of phages 29 2.11 Peptides synthesis 29 2.12 Immunohistochemical staining of phage binding to tumor mass of xenograft. 30 2.13 Conjugation of peptides to PEG-DSPE 31 2.14 Preparation of peptidyl Liposomes containing SRB, vinorelbin or doxorubicin 31 2.15 Endocytosis of liposome conjugates with EpEX synthetic peptides by HCT116 cells 33 2.16 MTT assay 33 2.17 In vivo tumor targeted therapeutic studies 34 2.18 Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) Assay 35 2.19 Vessel staining 35 2.20 Statistical analysis 36 Results 37 3.1 Expression and purification of Fc and EpEX-Fc recombinant proteins 37 3.2 Selection of phage-displayed random peptides targeting to EpEX-Fc 37 3.3 Generation of EpCAM knockdown colorectal cancer cell lines 38 3.4 Identification of phage clones specifically binding to HCT116 cells 38 3.5 In vivo tumor homing ability of selected phage clones. 39 3.6 Enhancement of liposomal SRB internalization by EpEX-SP1 and EpEX-SP2 40 3.7 Enhancement of liposomal drug intracellular delivery and cytotoxic effect in vitro by EpEX-SP1 and EpEX-SP2 41 3.8 Improvement of therapeutic efficacy by EpEX-SP1 and EpEX-SP2 in vivo 43 3.9 Expression and purification of soluble scFvs 44 3.10 Identification and verification of binding activity of EpEX-scFvs 45 3.11 Enhancement of internalization of liposomal SRB and liposomal drug by EpEX-scFv1 46 Discussion 47 Content of figures and tables 54 References 74 | |
dc.language.iso | en | |
dc.title | 研發以EpCAM為標的之藥物傳輸系統運用於大腸癌之治療 | zh_TW |
dc.title | Development of Anti-EpCAM Targeted Drug Delivery Systems for Treatment of Colon Cancer | en |
dc.type | Thesis | |
dc.date.schoolyear | 102-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 呂仁(Jean Lu),李文山(Wen-Shan Li),蕭培文(Pei-Wen Hsiao) | |
dc.subject.keyword | 大腸直腸癌,上皮細胞黏附因子及其細胞外域,噬菌體顯現法,標的胜?,單鏈抗體,藥物傳輸系統,微脂體藥物, | zh_TW |
dc.subject.keyword | colorectal cancer,EpCAM,EpEX,phage display,peptide,scFv,drug delivery systems,liposomal drug, | en |
dc.relation.page | 84 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2014-06-19 | |
dc.contributor.author-college | 牙醫專業學院 | zh_TW |
dc.contributor.author-dept | 口腔生物科學研究所 | zh_TW |
顯示於系所單位: | 口腔生物科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf 目前未授權公開取用 | 3.21 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。